Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Racquel D. Innis

Hematology Oncology
Birmingham Hematology Oncology Assoc LLC
1024 1st St N, 
Alabaster, AL 

Experienced in WT1-Related Wilms Tumor Syndromes
Birmingham Hematology Oncology Assoc LLC
1024 1st St N, 
Alabaster, AL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Racquel Innis is a Hematologist Oncology provider in Alabaster, Alabama. Dr. Innis is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Multiple Myeloma, Dehydration, Smoldering Multiple Myeloma, Iron Deficiency Anemia, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 9 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Student in an Organized Health Care Education/Training Program in VA
Hospital Affiliations
St Vincent's Chilton
Shelby Baptist Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MVP Health
  • EPO
  • PPO
Sutter Health
  • HMO
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VIVA Health
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

BIRMINGHAM HEMATOLOGY ONCOLOGY ASSOC LLC
1024 1st St N, Alabaster, AL 35007
Call: 205-664-4051

Additional Areas of Focus

Dr. Innis has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


6 Clinical Trials

A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
Enrollment Status: Completed
Publish Date: March 18, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Lenalidomide, Dexamethasone, Bortezomib
Study Phase: Phase 1/Phase 2
Phase II Study for Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplants from Matched Related Donors
Phase II Study for Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplants from Matched Related Donors
Enrollment Status: Active_not_recruiting
Publish Date: December 20, 2024
Intervention Type: Device
Study Phase: Not Applicable
The Myeloma Pack: A Multi-Modality Educational Intervention Strategy to Engage Patients With Multiple Myeloma
The Myeloma Pack: A Multi-Modality Educational Intervention Strategy to Engage Patients With Multiple Myeloma
Enrollment Status: Completed
Publish Date: November 25, 2024
Intervention Type: Other
Study Phase: Not Applicable
Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen
Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen
Enrollment Status: Completed
Publish Date: January 12, 2024
Intervention Type: Drug, Procedure
Study Drug: Fludarabine
Study Phase: Phase 2
Phase II Clinical Trial of the Use of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GvHD) Prophylaxis Following Matched Unrelated Donor (MUD) and Mismatched Unrelated Donor (MMUD)Hematopoietic Stem Cell Transplant (HSCT)
Phase II Clinical Trial of the Use of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GvHD) Prophylaxis Following Matched Unrelated Donor (MUD) and Mismatched Unrelated Donor (MMUD)Hematopoietic Stem Cell Transplant (HSCT)
Enrollment Status: Completed
Publish Date: September 30, 2022
Intervention Type: Drug
Study Drug: Cyclophosphamide
Study Phase: Phase 2
Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)
Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)
Enrollment Status: Completed
Publish Date: April 25, 2019
Intervention Type: Device
Study Phase: Not Applicable
View 5 Less Clinical Trials

9 Total Publications

Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer.
Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer.
Journal: Journal for immunotherapy of cancer
Published: May 25, 2022
View All 9 Publications
Similar Doctors
Mollie R. Deshazo
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Mollie R. Deshazo
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Mollie R. Deshazo
Hematology Oncology | Hematology | Oncology

University Of Alabama Health Services Foundation, PC

619 19th St S, 
Birmingham, AL 
 (17.3 miles away)
205-934-4011
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mollie Deshazo is a Hematologist Oncology specialist and a Hematologist in Birmingham, Alabama. Dr. Deshazo is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Renal Cell Carcinoma (RCC), Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, and Chromophobe Renal Cell Carcinoma. Dr. Deshazo is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Cara C. Bondly
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Cara C. Bondly
Hematology Oncology | Hematology | Oncology

Birmingham Hematology Oncology Assoc LLC

2728 10th S Ave, Suite 200, 
Birmingham, AL 
 (17.5 miles away)
205-939-7800
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Cara Bondly is a Hematologist Oncology specialist and a Hematologist in Birmingham, Alabama. Dr. Bondly is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Childhood Iron Deficiency Anemia, Angiosarcoma, and Bone Marrow Aspiration. Dr. Bondly is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Lisle M. Nabell
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Lisle M. Nabell
Hematology Oncology | Hematology | Oncology

University Of Alabama Health Services Foundation, PC

619 19th St S, 
Birmingham, AL 
 (17.3 miles away)
205-934-4011
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Lisle Nabell is a Hematologist Oncology specialist and a Hematologist in Birmingham, Alabama. Dr. Nabell is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, Bone Marrow Aspiration, and Gastrostomy. Dr. Nabell is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Innis's expertise for a condition
ConditionClose
    • Distinguished
    • Bone Marrow Transplant
      Dr. Innis is
      Distinguished
      . Learn about Bone Marrow Transplant.
      See more Bone Marrow Transplant experts
    • Dehydration
      Dr. Innis is
      Distinguished
      . Learn about Dehydration.
      See more Dehydration experts
    • Multiple Myeloma
      Dr. Innis is
      Distinguished
      . Learn about Multiple Myeloma.
      See more Multiple Myeloma experts
    • Advanced
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Innis is
      Advanced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Innis is
      Advanced
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    • Anemia
      Dr. Innis is
      Advanced
      . Learn about Anemia.
      See more Anemia experts
    • Breast Cancer
      Dr. Innis is
      Advanced
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Childhood Iron Deficiency Anemia
      Dr. Innis is
      Advanced
      . Learn about Childhood Iron Deficiency Anemia.
      See more Childhood Iron Deficiency Anemia experts
    • Graft Versus Host Disease (GvHD)
      Dr. Innis is
      Advanced
      . Learn about Graft Versus Host Disease (GvHD).
      See more Graft Versus Host Disease (GvHD) experts
    View All 15 Advanced Conditions
    • Experienced
    • Acute Lymphoblastic Leukemia (ALL)
      Dr. Innis is
      Experienced
      . Learn about Acute Lymphoblastic Leukemia (ALL).
      See more Acute Lymphoblastic Leukemia (ALL) experts
    • Acute Mountain Sickness
      Dr. Innis is
      Experienced
      . Learn about Acute Mountain Sickness.
      See more Acute Mountain Sickness experts
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Innis is
      Experienced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myelomonocytic Leukemia
      Dr. Innis is
      Experienced
      . Learn about Acute Myelomonocytic Leukemia.
      See more Acute Myelomonocytic Leukemia experts
    • Acute Promyelocytic Leukemia
      Dr. Innis is
      Experienced
      . Learn about Acute Promyelocytic Leukemia.
      See more Acute Promyelocytic Leukemia experts
    • Adult Soft Tissue Sarcoma
      Dr. Innis is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    View All 141 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved